HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Biochemical and pathological evidences on the benefit of a new biodegradable nanoparticles of probiotic extract in murine colitis.

Abstract
Efficacy of probiotics in the management of human inflammatory bowel disease (IBD) has been approved in the recent years. In the present work, the efficacy of a new biodegradable nanoparticles (NPs) of encapsulated and lyophilized probiotic extract (LPE) was examined in murine colitis. Colitis was induced by rectal instillation of trinitrobenzen sulfonic acid to male Wistar rats. The safety and effective dose of LPE was determined in a pilot study. To ease delivery into colon, LPE was encapsulated in chitosan-coated-poly (lactide co glycolide acid) NPs. After induction of colitis, animals in different groups received test compound in three doses by gavage for 10 days. Groups of sham, control (saline), and standard (dexamethasone) were also assigned. Colonic pathological examination, tumor necrosis factor alpha, interlukin (IL)-1β, myeloperoxidase (MPO), and lipid peroxidation (LPO) were performed. LPE at all doses (273, 545, and 1100 mg/kg) had positive effects in reduction of pro-inflammatory cytokines, LPO, and MPO in a dose-dependent manner. The formulated compound containing medium dose of LPE was more efficient in mitigating the experimental colitis in comparison with that of high-dose LPE. It is concluded that LPE and its nanoparticle-encapsulated form are very much effective in control of colitis. Regarding safety of this compound, further studies can be conducted in patients with IBD.
AuthorsAfrooz Saadatzadeh, Fatemeh Atyabi, Mohammad Reza Fazeli, Rassoul Dinarvand, Hossein Jamalifar, Amir Hossein Abdolghaffari, Parvin Mahdaviani, Mirgholamreza Mahbod, Maryam Baeeri, Amir Baghaei, Azadeh Mohammadirad, Mohammad Abdollahi
JournalFundamental & clinical pharmacology (Fundam Clin Pharmacol) Vol. 26 Issue 5 Pg. 589-98 (Oct 2012) ISSN: 1472-8206 [Electronic] England
PMID21771055 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2011 The Authors Fundamental and Clinical Pharmacology © 2011 Société Française de Pharmacologie et de Thérapeutique.
Chemical References
  • Cytokines
  • Inflammation Mediators
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Polyglycolic Acid
  • Lactic Acid
  • Dexamethasone
  • Trinitrobenzenesulfonic Acid
  • Chitosan
Topics
  • Animals
  • Chitosan (chemistry)
  • Colitis (pathology, therapy)
  • Cytokines (metabolism)
  • Dexamethasone (therapeutic use)
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Freeze Drying
  • Inflammation Mediators (metabolism)
  • Lactic Acid (chemistry)
  • Lipid Peroxidation
  • Male
  • Nanoparticles
  • Pilot Projects
  • Polyglycolic Acid (chemistry)
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Probiotics (administration & dosage, therapeutic use, toxicity)
  • Rats
  • Rats, Wistar
  • Trinitrobenzenesulfonic Acid

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: